CARDION AG expands executive board

10-Jan-2002

Erkrath, Germany. The transatlantic biopharmaceutical company CARDION AG, with operating entities in Erkrath and Boston (USA), expanded its executive board effective January 1, 2002. In addition to CARDION´s Chief Executive Officer Dr. Michael Ruhl, Mr. Niels Ackermann and Dr. Manfred Rüdiger have been appointed to become members of CARDION?s executive board: · Niels Ackermann, Chief Financial Officer, previously worked in the investment banking division of Goldman Sachs where he gained extensive experience in the mergers & acquisitions business as well as the preparation of initial public offerings of German companies at the Neuer Markt and NASDAQ. He joined CARDION in September 2001 and took over the position of CFO at the same time. · Dr. Manfred Rüdiger, Chief Scientific Officer, joined CARDION in 1998. Since then he has played a significant role in strengthening the company?s therapeutic focus on inflammatory and cardiovascular disorders. Following his appointment Dr. Rüdiger will hold responsibility for the research & development process from drug discovery to phase IIa of clinical development. CARDION AG is a uniquely positioned biopharmaceutical company that concentrates on the development of innovative, potentially curative therapeutics for the treatment of inflammatory and cardiovascular diseases. CARDION, founded in 1996, is focusing on highly attractive, rapidly growing areas: a novel immunotherapeutic protein for the treatment of rheumatoid arthritis and other Inflammatory diseases, cardiovascular disorders and a stem cell platform for the creation of regenerative medicine products (with initial focus on the treatment of Type I diabetes).

https://www.bionity.com/en/news/7075/cardion-ag-expands-executive-board.html